Evidence strength for the context described on this page.
PEPTIDE ATLAS / ENERGY & LONGEVITY / MOTS-C
Not FDA-approvedPreclinical
MOTS-c
ALSO KNOWN ASMitochondrial open-reading-frame peptide
A mitochondrial-derived peptide with intriguing biology but no identified human exposure data for marketed products.
01CATEGORYEnergy & longevity
02REGULATORY STATUSNot FDA-approved
03COMMON ROUTEMarketed for subcutaneous injection; not approved
04DOSE BASISReported clinic use only
HOW TO USE THIS PAGE
Read the profile in the order that protects the decision.
- 01Verify what it is
Confirm the exact molecule, route, regulatory lane and actual human evidence.
- 02Read limits before dose
Unsupported claims, contraindications and uncertainty come before any protocol.
- 03Build the monitoring plan
Define the target, baseline checks, reassessment point and stop rules with a qualified clinician.
This peptide does not have an FDA-approved product or dose for the claims described here. Research dosing and vendor protocols are not consumer prescribing guidance.
RESEARCH PASSPORT
The five facts to know first.
REVIEWED
JULY 2026
Status is product-, formulation- and indication-specific.
Trial, label or reported-practice basis is always named.
Official labels, regulators, trials and indexed literature where available.
Peptide hormones, growth factors and related substances may be prohibited.
Check Global DRO ↗OVERVIEW
What MOTS-c is.
A short peptide encoded within mitochondrial DNA and studied as a metabolic signaling molecule. Online products jump from animal biology to human anti-aging claims without the clinical bridge.
HOW IT IS THOUGHT TO WORK
Proposed to influence cellular stress responses, AMPK-linked metabolism, glucose handling and exercise adaptation.
EFFECTS & EVIDENCE
What the evidence supports—and what it does not.
- Preclinical metabolic effects
- No established human energy, fat-loss, performance or longevity benefit
- Improved exercise performance
- Fat loss
- Insulin-sensitivity treatment
- Longer life or slower aging
Evidence grade: Preclinical. For an approved drug, “high” refers only to its labeled indication—not every off-label or wellness claim.
DOSAGE CONTEXT
Best available dosing range.
Reported clinic use onlyMost commonly reported clinic protocols: 5 mg subcutaneously every 5 days for four doses, or 5 mg twice weekly for about 8 weeks. FDA has identified no human exposure data for MOTS-c drug products, so these are clinic conventions—not FDA-approved or validated human regimens.
BEST AVAILABLE GENERIC RANGE
Men and women.
The basis is named above. Reported-use ranges describe what clinics or communities publish; they are not proof of safety, efficacy, legality or product quality.
- Schedule in that source context
- Published clinic protocols vary from four 5 mg injections over 20 days to 5 mg twice weekly for 8 weeks, often followed by a long break.
- How to interpret it
- The wide protocol variation is itself evidence of uncertainty. FDA reports no identified human exposure data, and animal exercise/metabolic studies cannot establish a human dose.
- Route
- Marketed for subcutaneous injection; not approved
- Duration
- Reported cycles range from 20 days to 8 weeks; no established course
- Men & women
- No human dose or sex-specific safety data. The same reported clinic numbers are generally used for men and women without validation.
Clinician verification required. Always double-check the exact molecule or salt, concentration, route, volume, schedule, indication, patient-specific contraindications, interactions and applicable law with the prescribing clinician and dispensing pharmacy. A disclaimer does not make an unapproved product FDA-approved, and a reported-use range is not a prescription.
MONITORING
What should be tracked.
- No validated clinical monitoring framework
SAFETY
Risks, red flags and reasons to avoid it.
- Unknown human toxicity
- Immunogenicity and peptide impurities
- Misidentification, contamination and sterility problems
- Unpredictable metabolic effects
- Human use outside approved research
- Self-injection
- Pregnancy
- Replacing evidence-based metabolic care
Stop and seek careGet urgent medical help for trouble breathing, facial or throat swelling, chest pain, fainting, severe persistent abdominal pain, neurologic changes, severe hypoglycemia, uncontrolled vomiting or a prolonged painful erection.
CLINICIAN VISIT CHECKLIST
Six questions worth bringing with you.
Molecule or analog, salt, concentration, route, manufacturer or compounder, lot and beyond-use date.
Name the diagnosis or target, how it will be measured and the realistic time to reassess.
Ask how it compares with FDA-approved, lower-risk or better-studied alternatives.
Label, human trial, specialty guideline or clinic convention—and whether that route and formulation match.
Baseline checks, follow-up measures, interactions, pregnancy considerations and symptoms that mean stop.
Pharmacy license, prescription, identity/potency testing, sterility controls and who handles a product complaint.
Do not improvise reconstitution or convert “units” without the exact concentration. Mixing, storage and beyond-use instructions are product-specific; confirm them with the dispensing pharmacy.
PRIMARY SOURCES
Read the record yourself.
We prioritize official prescribing information, FDA regulatory material, registered trials and indexed biomedical literature. A source supports the specific statement beside it—not every claim made about the molecule.
PRODUCTS & TREATMENT ACCESS
There is no product we can responsibly recommend.
Research-chemical and some compounded marketing; not FDA-approved.
Mitochondrial origin is scientifically interesting, but it is not proof of a safe mitochondrial upgrade.
Evidence before affiliate revenue.
We do not rank or sell unapproved research peptides. Use the Atlas to discuss safer, evidence-backed alternatives with a qualified clinician.
Explore evidence-backed options →NEXT STEP